The Interplay Between FDA Approval And Discovery Rule

Law360, New York (March 8, 2012, 1:26 PM EST) -- Adopting a middle-of-the-road approach that may raise more questions than it answers, the New Jersey Supreme Court has ruled that U.S. Food and Drug Administration (FDA) approval of drug and medical device warnings creates a presumption against application of the discovery rule to a defendant's otherwise-valid statute of limitations defense.

New Jersey's Product Liability Act (PLA) creates a rebuttable presumption that warnings or instructions approved by the FDA are adequate. Indeed, in discussing the impact of this presumption on the merits of a plaintiff's failure-to-warn claim, the state Supreme Court said in its 1999 opinion in Perez v. Wyeth Labs Inc....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!